Compare TLYS & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLYS | PRPO |
|---|---|---|
| Founded | 1982 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.3M | 44.4M |
| IPO Year | 2011 | 2000 |
| Metric | TLYS | PRPO |
|---|---|---|
| Price | $4.52 | $30.50 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 425.2K | 14.9K |
| Earning Date | 06-03-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 62.34 | ★ 92.15 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $24,049,000.00 |
| Revenue This Year | $4.66 | N/A |
| Revenue Next Year | $1.74 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $0.57 | $5.94 |
| 52 Week High | $5.54 | $32.40 |
| Indicator | TLYS | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 55.97 | 55.33 |
| Support Level | $3.67 | $22.96 |
| Resistance Level | $5.54 | N/A |
| Average True Range (ATR) | 0.34 | 1.71 |
| MACD | -0.14 | 0.15 |
| Stochastic Oscillator | 44.12 | 61.12 |
Tilly's Inc works as a specialty retailer of casual apparel, footwear, and accessories for young men, young women, boys, and girls. It offers an unparalleled selection of relevant brands, styles, colors, sizes, and price points. It delivers branded fashion, and core styles for tops, outerwear, bottoms, and dresses. It also provides backpacks, hats, sunglasses, headphones, handbags, watches, and jewelry. It markets its products under the brand names of Vans, RVCA, Adidas, Nike SB, and Hurley among others. It operates its stores in malls, lifestyle centers, power centers, community centers, outlet centers, street-front locations, and also through e-commerce.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.